查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997402

核子醫學掃描術診斷設備市場：依產品、放射性藥物、應用和最終用戶分類－2026-2032年全球市場預測

Nuclear Imaging Equipment Market by Product, Radiopharmaceuticals, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，核子醫學掃描術診斷設備市場價值將達到 62.9 億美元，到 2026 年將成長至 66.6 億美元，到 2032 年將達到 95.5 億美元，複合年成長率為 6.14%。

主要市場統計數據
基準年 2025 62.9億美元
預計年份：2026年 66.6億美元
預測年份 2032 95.5億美元
複合年成長率 (%) 6.14%

本文簡要概述了技術創新、營運壓力和不斷變化的臨床需求如何重塑核子醫學掃描術診斷設備的採用和普及。

核子醫學掃描術診斷領域正處於變革的關鍵時期，技術創新、不斷變化的臨床需求和政策環境的交匯正在重塑診斷和治療路徑。檢測器材料、重建演算法和混合成像架構的進步提高了核醫學影像的敏感度和特異性，使臨床醫生能夠更早發現病灶，並更深入地了解疾病的生物學特徵。同時，放射性藥物生產和分銷網路的成熟擴大了可用示蹤劑的範圍，從而拓展了臨床適應症，並推動了對特定成像方式設備的需求。

模態融合、放射性藥物多樣化和人工智慧驅動的分析如何從整體重新定義臨床工作流程、經營模式和夥伴關係策略。

核子醫學影像領域正經歷一場變革，這場變革由三個相互關聯的因素所驅動：影像方式的整合、放射性藥物的多樣化以及計算技術的進步。影像系統的混合化已不再侷限於單一功能的升級，而是逐漸成為一項基本的架構原則。 PET/CT 和 SPECT/CT 整合平台能夠實現解剖學和觀察觀察之間的無縫關聯，從而提高診斷的準確性和檢查效率。同時，放射性藥物工具包也在不斷擴展，納入了高度標靶特異性的示蹤劑和診療整合（治療診斷）組合，將診斷與標靶治療相結合。這正在改變影像中心和腫瘤診所的臨床路徑和資金投入需求。

評估 2025 年實施的關稅政策如何改變了核子醫學掃描術診斷設備相關人員的供應鏈、採購行為和策略採購。

2025年實施的關稅政策為核子醫學掃描術診斷生態系統帶來了新的成本和物流複​​雜性，其影響波及設備採購、備件庫存以及放射性藥物的整個供應鏈。進口影像組件和製造投入品關稅的提高迫使供應商重新思考其全球採購策略，加速了關於近岸組裝、供應商多元化以及重新談判長期供應商合約的討論。重要的是，這一趨勢也影響臨床醫生的資本規劃時間，許多醫生現在開始將更長的前置作業時間週期和更高的總成本納入設備升級和擴建的決策考慮。

透過細分市場洞察，揭示產品類型、放射性藥物類別、臨床應用和最終用戶類型如何相互作用，從而確定採購優先順序和營運權衡。

逐一細分市場分析市場動態，揭示了每種產品、示蹤劑、臨床環境和最終用戶的獨特實際情況，這些情況都會影響投資決策和營運設計。就產品架構而言，平面閃爍顯像系統繼續適用於較簡單的診斷流程，而正子斷層掃描 (PET) 掃描儀則提供高靈敏度的功能性影像，這對於先進的腫瘤學和神經學應用至關重要。單光子發射電腦斷層掃描 (SPECT) 掃描儀則處於中間位置，混合型 SPECT 影像系統透過 CT 配抗蝕劑擴展了診斷功能，而獨立式 SPECT 平台則為優先考慮處理能力的機構提供了經濟高效的解決方案。這些產品差異決定了不同臨床環境下的採購決策。

本研究從區域觀點考察了美洲、歐洲、中東和非洲以及亞太地區的法規結構、還款趨勢和製造地如何影響採用率和夥伴關係選擇。

區域趨勢影響著美洲、歐洲、中東和非洲以及亞太地區的應用曲線、監管複雜性和供應鏈選擇，每個地區都有其獨特的應用條件和策略機會。在美洲，成熟的報銷框架和密集的轉診網路正在推動先進PET平台和混合系統的快速普及。同時，積極的臨床研究正在加速新型示蹤劑和治療診斷學工作流程的早期應用。相較之下，一些公共醫療機構的資金限制正在推動開發資金籌措方案和管理服務協議，以降低初始成本，同時確保能夠獲得最先進的影像能力。

領先的供應商和服務供應商如何將與硬體、軟體和放射性藥物的夥伴關係整合起來，以創建穩健的、經常性的收入模式，並在競爭中脫穎而出？

核子醫學掃描術診斷生態系統中的主要企業正在重新評估其策略，重點關注整合硬體、放射性藥物利用和軟體主導的臨床工作流程的綜合價值提案。供應商越來越重視可維護性和運作保證，因為他們認知到設備生命週期經濟性和營運連續性對醫院和診斷中心至關重要。與放射性藥物製造商和物流供應商建立策略合作夥伴關係是確保端到端解決方案的關鍵，該解決方案將示踪劑供應和掃描儀部署連接起來，從而縮短患者等待時間並簡化臨床排班。

為醫療保健提供者、製造商和投資者制定可操作的策略重點，以增強供應鏈韌性、加快軟體採用率，並將資本配置與臨床價值連結起來。

產業領導者應優先採取三項策略行動，以平衡短期韌性與價值導向個人化醫療導向的長期定位。首先，實現採購多元化並加強與供應商的關係，以減輕關稅造成的供應中斷。這包括對關鍵零件進行選擇性近岸外包，同時保持多個專業零件和耗材供應商。其次，加快軟體和分析工具的投資，以提高掃描器的使用率和診斷處理能力。檢驗的人工智慧工具和定量報告系統可以顯著降低營運成本並提升臨床效果，從而支援差異化採購策略。

為了檢驗策略見解和假設，我們採用了嚴謹的混合方法研究途徑，結合了專家訪談、醫療設備分析、監管審查和供應鏈映射。

本次高階主管綜合報告的基礎研究採用跨學科方法，結合一手和二手研究，建構了可靠的證據基礎。一手研究包括對臨床終端使用者、採購經理和服務工程師進行結構化訪談，以了解營運限制、培訓需求和運作優先事項。這些定性見解與設備規格、臨床試驗結果和監管核准趨勢的技術分析相結合，以評估不同平台類型之間的功能差異。供應鏈圖譜確定了組件和示蹤劑分銷的關鍵節點，情境分析則考察了政策變化和關稅相關的成本波動敏感性。

整合的臨床路徑如何提供韌性，以及檢驗的軟體解決方案如何發揮作用，將決定核子醫學掃描術診斷設備市場的長期領導地位。

總而言之，核子醫學掃描術診斷設備市場正從以設備為中心的市場向一體化的臨床生態系統轉變，放射性藥物的供應、軟體智慧和供應鏈韌性決定著其長期成功。混合成像和演算法重建技術的進步拓展了診斷能力，同時也提高了營運整合和臨床檢驗的標準。關稅帶來的複雜情況給採購和物流帶來了新的短期壓力，但也促使企業進行策略調整，從長遠來看，這些調整有望建立更具韌性的供應鍊和本地化能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章核子醫學掃描術診斷設備市場：依產品分類

  • 平面閃爍成像系統
  • 正子斷層掃描（PET）掃描儀
  • 單光子發射電腦斷層掃描（SPECT）掃描儀
    • 混合SPECT影像系統
    • 獨立式SPECT影像系統

第9章：核子醫學掃描術診斷設備市場

  • 氟代脫氧葡萄糖（FDG）
  • 鎵-68
  • 碘-131
  • Technetium-99m

第10章：核子醫學掃描術診斷設備市場：依應用領域分類

  • 循環系統
  • 感染疾病診斷
  • 神經病學
  • 腫瘤學
  • 整形外科

第11章核子醫學掃描術診斷設備市場：依最終用戶分類

  • 診斷影像中心
  • 醫院和診所
  • 研究機構

第12章核子醫學掃描術診斷設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章核子醫學掃描術診斷設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章核子醫學掃描術診斷設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國核子醫學掃描術診斷設備市場

第16章：中國核子醫學掃描術診斷設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Absolute Imaging Inc.
  • Advanced Accelerator Applications SA by Norvatis
  • Agfa-Gevaert NV
  • Bayer AG
  • Bozlu Holding AS
  • Bracco Imaging SpA
  • Canon Medical Systems Corporation
  • CMR Naviscan Corporation
  • Cubresa Inc.
  • DDD-Diagnostic A/S
  • Digirad Corporation
  • Edge Medical Solutions Private Limited
  • GE HealthCare Technologies Inc.
  • Koninklijke Philips NV
  • Mediso Ltd.
  • MR Solutions Ltd.
  • Neusoft Medical Systems Co., Ltd.
  • PerkinElmer Inc.
  • Revvity Inc
  • Rigaku Corporation
  • Shimadzu Corporation
  • Siemens AG
  • Surgiceye GmbH
  • United Imaging Healthcare Co., Ltd.
Product Code: MRR-50124643717F

The Nuclear Imaging Equipment Market was valued at USD 6.29 billion in 2025 and is projected to grow to USD 6.66 billion in 2026, with a CAGR of 6.14%, reaching USD 9.55 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.29 billion
Estimated Year [2026] USD 6.66 billion
Forecast Year [2032] USD 9.55 billion
CAGR (%) 6.14%

A concise framing of how technological innovation operational pressures and evolving clinical needs are reshaping nuclear imaging equipment deployment and adoption

The field of nuclear imaging equipment stands at an inflection point where technological innovation, evolving clinical needs, and shifting policy environments converge to reshape diagnostic and therapeutic pathways. Advances in detector materials, reconstruction algorithms, and hybrid imaging architectures have elevated both the sensitivity and specificity of nuclear scans, enabling clinicians to detect pathology earlier and to characterize disease biology with greater granularity. At the same time, the maturation of radiopharmaceutical manufacturing and distribution networks has expanded the portfolio of available tracers, which in turn broadens clinical indications and drives demand for modality-specific instrumentation.

Despite these technical gains, stakeholders face increasing complexity in procurement decisions, operational workflows, and capital allocation. Imaging service providers must balance investments in cutting-edge PET and SPECT platforms against the realities of staffing, reagent availability, and reimbursement frameworks. Consequentially, leaders across clinical, operational, and commercial functions require evidence-based intelligence that links device capability to clinical impact and operational feasibility. This executive summary synthesizes those dynamics, highlighting structural shifts, regulatory and trade influences, segmentation-level insights, regional considerations, and practical recommendations that equip decision-makers to navigate the near-term landscape with clarity and confidence.

How modality convergence radiopharmaceutical diversification and AI-driven analytics are collectively redefining clinical workflows commercial models and partnership strategies

The nuclear imaging landscape is undergoing transformative shifts driven by three interrelated vectors: modality convergence, radiopharmaceutical diversification, and computational augmentation. Hybridization of imaging systems has moved beyond single-point upgrades to become a dominant architectural principle, with integrated PET/CT and SPECT/CT platforms enabling seamless anatomical-functional correlation that improves diagnostic confidence and procedural efficiency. Concurrently, the radiopharmaceutical toolkit has expanded to incorporate tracers with higher target specificity and theranostic pairings that link diagnosis to targeted therapy, thereby altering clinical pathways and capital requirements for imaging centers and oncology clinics.

Complementing hardware and tracer innovation, advances in artificial intelligence and quantitative analytics are changing how images are reconstructed, interpreted, and integrated into clinical decision-making. Machine learning-driven denoising and lesion detection improve effective throughput and reduce repeat scans, while standardized quantitative metrics enhance longitudinal patient monitoring. Regulatory agencies are increasingly defining pathways for software-as-a-medical-device approvals, prompting vendors to reorient product roadmaps toward validated algorithmic components. Moreover, supply chain resiliency and localized manufacturing initiatives are shifting procurement behavior, encouraging strategic partnerships between equipment manufacturers, radiopharmaceutical producers, and service organizations. Taken together, these shifts create a landscape in which clinical value, workflow integration, and ecosystem partnerships determine long-term leadership rather than device specifications alone.

Assessment of how tariff policy enacted in 2025 has altered supply chains procurement behavior and strategic sourcing among nuclear imaging equipment stakeholders

Tariff policy implemented in 2025 introduced a new layer of cost and logistical complexity for the nuclear imaging ecosystem, with ramifications reverberating across device procurement, spare-parts inventory, and radiopharmaceutical supply chains. Increased duties on imported imaging components and manufacturing inputs have pressured vendors to reassess global sourcing footprints, accelerating conversations about nearshoring assembly, diversifying supplier bases, and renegotiating long-term supplier agreements. Importantly, this dynamic has also influenced capital planning horizons for clinical providers, many of whom are now factoring extended lead times and higher landed costs into replacement and expansion decisions.

Beyond hardware, tariffs have affected the movement of radiopharmaceutical-related consumables and specialized hardware modules, prompting some suppliers to consolidate logistics and to pursue simplified product configurations that reduce dependency on tariffed components. In response, purchasers have adopted a mix of mitigation strategies including expanded service contracts to preserve uptime, selective inventory buffers for critical spare parts, and greater use of multi-year procurement agreements to lock in pricing predictability. Policy-driven cost inflation has also accelerated demand for value-based procurement models, wherein equipment selection criteria emphasize throughput, reagent efficiency, and serviceability over headline specifications. While tariffs introduce short-term cost pressures, they have also catalyzed structural shifts that may improve long-term supply resilience through localized supply networks and strategic vendor partnerships.

Segment-aware intelligence revealing how product categories radiopharmaceutical classes clinical applications and end-user types jointly determine procurement priorities and operational trade-offs

Segment-focused interpretation of market dynamics reveals distinct product, tracer, clinical, and end-user realities that influence investment decisions and operational design. Within product architecture, planar scintigraphy imaging systems continue to serve lower-complexity diagnostic workflows, while positron emission tomography scanners deliver high-sensitivity functional imaging essential for advanced oncology and neurology applications. Single Photon Emission Computed Tomography scanners occupy a middle ground where hybrid SPECT imaging systems extend diagnostic capability through CT co-registration and stand-alone SPECT platforms offer cost-effective solutions for centers prioritizing throughput. These product distinctions drive procurement logic across diverse clinical settings.

Radiopharmaceutical availability and characteristics exert a parallel influence. Fluorodeoxyglucose remains a central workhorse tracer for metabolic imaging, whereas Gallium-68's utility in peptide receptor imaging and novel theranostic applications has increased clinical demand for on-site or regional generator solutions. Iodine-131 retains relevance for established therapeutic indications, and Technetium-99m continues to underpin a broad array of routine scintigraphic studies due to its favorable physical properties and wide distribution infrastructure. Clinically, cardiology and oncology dominate utilization patterns for high-end modalities, with neurology and infectious disease diagnosis requiring specialized tracers and protocols. Orthopedics relies more on planar and SPECT techniques for targeted evaluations. End-user distinctions matter: diagnostic imaging centers prioritize throughput and multi-modality capability to serve referral networks, hospitals and clinics require integration with broader electronic medical records and interventional suites, and research institutes demand flexible platforms that support investigational tracers and rapid protocol changes. Aligning product selection with tracer strategy, clinical indication, and end-user operational constraints is essential to optimize returns on capital and clinical impact.

A regional lens on how regulatory frameworks reimbursement dynamics and manufacturing footprints across Americas EMEA and Asia-Pacific drive differentiated adoption and partnership choices

Regional dynamics shape adoption curves, regulatory complexity, and supply-chain choices across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each geography presenting unique deployment conditions and strategic opportunities. In the Americas, mature reimbursement frameworks and high-density referral networks favor rapid uptake of advanced PET platforms and hybrid systems, while strong clinical research activity drives early adoption of novel tracers and theranostic workflows. Conversely, capital constraints at some public facilities encourage financing options and managed service agreements that reduce upfront expenditure while preserving access to modern imaging capability.

Europe, Middle East & Africa present a heterogeneous set of regulatory and reimbursement environments where centralized health technology assessment processes in some jurisdictions drive rigorous value demonstration, and in others, emerging markets exhibit demand for cost-efficient SPECT and planar systems. The region's diversity also creates opportunities for platform standardization that supports multinational clinical trials and cross-border service models. In the Asia-Pacific region, rapid expansion of diagnostic infrastructure, investments in local radiopharmaceutical production, and strong government interest in domestic manufacturing have accelerated deployment of both PET and SPECT systems. These markets are characterized by a combination of high-volume clinical demand and an appetite for integrated service models, including remote monitoring and AI-enabled workflow optimization. Across regions, regulatory pathways for software and radiopharmaceutical approval, reimbursement policy shifts, and local manufacturing capabilities will continue to drive differentiated adoption patterns and partnership models.

How major vendors and service providers are integrating hardware software and radiopharmaceutical partnerships to create resilient recurring-revenue models and competitive differentiation

Leading organizations in the nuclear imaging equipment ecosystem are realigning strategies around integrated value propositions that combine hardware, radiopharmaceutical enablement, and software-driven clinical workflows. Vendors are placing greater emphasis on serviceability and uptime guarantees, recognizing that equipment lifecycle economics and operational continuity are decisive factors for hospitals and diagnostic centers. Strategic alliances with radiopharmaceutical manufacturers and logistics providers have become frontline tactics to secure end-to-end solutions that link tracer availability with scanner deployment, thereby reducing patient wait times and simplifying clinical scheduling.

In parallel, a cohort of companies is investing heavily in scalable software platforms to deliver quantitative imaging, decision support, and remote monitoring services. These offerings are designed to create sticky revenue streams and to enable performance-based contracts tied to throughput, diagnostic accuracy, or treatment planning efficacy. Companies are also experimenting with flexible commercial models including pay-per-scan arrangements and subscription-based access to premium analytics, which appeal to resource-constrained buyers. Finally, successful players prioritize regulatory strategy and clinical evidence generation, partnering with academic centers to validate new tracers, reconstruction algorithms, and theranostic pathways that support differentiated value propositions in competitive procurement processes.

Actionable strategic priorities for providers manufacturers and investors to enhance supply resilience accelerate software adoption and link capital deployment to clinical value

Industry leaders should prioritize a triage of strategic actions that balance near-term resilience with long-term positioning for value-based, personalized care. First, diversify sourcing and strengthen supplier relationships to mitigate tariff-induced supply disruptions; engage in selective nearshoring for critical components while maintaining multi-sourced options for specialized parts and consumables. Second, accelerate investments in software and analytics that improve scanner utilization and diagnostic throughput; validated AI tools and quantitative reporting systems can materially reduce operational costs and improve clinical impact, thereby supporting differentiated procurement justifications.

Third, cultivate strategic partnerships with radiopharmaceutical manufacturers and logistics providers to ensure tracer availability aligns with clinical schedules and to enable integrated service offerings. Fourth, adopt flexible commercial models that reduce capital barriers for buyers, such as managed service contracts, outcome-linked pricing, and modular upgrade paths that extend device lifecycles. Fifth, engage proactively with regulators and payers through robust evidence generation and health economic demonstration projects to secure favorable reimbursement and to streamline approvals for software-enabled features. Collectively, these actions will support sustainable growth while improving access to advanced diagnostic and theranostic workflows for diverse care settings.

A rigorous mixed-methods research approach combining expert interviews device analytics regulatory review and supply-chain mapping to validate strategic insights and assumptions

The research underpinning this executive synthesis combined a multidisciplinary approach incorporating primary and secondary inputs to create a robust evidence base. Primary research included structured interviews with clinical end-users, procurement leaders, and service engineers to capture operational constraints, training needs, and uptime priorities. These qualitative insights were triangulated with technical analyses of device specifications, clinical trial outcomes, and regulatory approval trends to assess capability differentials among platform types. Supply chain mapping identified critical nodes for components and tracer distribution, while scenario analysis explored sensitivity to policy shifts and tariff-related cost movements.

Secondary research drew on peer-reviewed clinical literature, regulatory filings, patent databases, and public disclosures from manufacturers and healthcare providers to validate assertions regarding technology performance and clinical utility. Where applicable, clinical guideline updates and published comparative effectiveness studies informed assessments of tracer-specific value propositions. Throughout the research process, methodological rigor was maintained through iterative validation with subject-matter experts and by documenting data provenance and analytical assumptions. The outcome is a synthesized perspective designed to inform strategic decision-making without relying on proprietary or proprietary forecasting outputs.

Synthesis of how integrated clinical pathways supply resilience and validated software offerings will determine long-term leadership in nuclear imaging equipment markets

In summary, the nuclear imaging equipment landscape is evolving from a device-centric market into an integrated clinical ecosystem where radiopharmaceutical availability, software intelligence, and supply-chain resilience determine long-term success. Technological advances in hybrid imaging and algorithmic reconstruction have expanded diagnostic capability while also raising the bar for operational integration and clinical validation. Tariff-driven complexities introduced new short-term pressures on procurement and logistics, but they also incentivized strategic adjustments that may yield more resilient supply architectures and localized capability over time.

Decision-makers should therefore align investment choices with clinical use cases, operational constraints, and regional regulatory realities. By privileging solutions that combine diagnostic accuracy, workflow efficiency, and service robustness, providers can deliver improved patient outcomes while containing total cost of ownership. Manufacturers and investors that focus on integrated offerings, flexible commercial arrangements, and validated software components will be positioned to capture enduring value as care pathways increasingly depend on precise molecular imaging and theranostic alignment. The path forward requires collaborative ecosystems, evidence-driven product design, and pragmatic commercial models that translate technological promise into measurable clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Imaging Equipment Market, by Product

  • 8.1. Planar Scintigraphy Imaging Systems
  • 8.2. Positron Emission Tomography (PET) Scanners
  • 8.3. Single Photon Emission Computed Tomography (SPECT) Scanners
    • 8.3.1. Hybrid SPECT Imaging Systems
    • 8.3.2. Standalone SPECT Imaging Systems

9. Nuclear Imaging Equipment Market, by Radiopharmaceuticals

  • 9.1. Fluorodeoxyglucose (FDG)
  • 9.2. Gallium-68
  • 9.3. Iodine-131
  • 9.4. Technetium-99m

10. Nuclear Imaging Equipment Market, by Application

  • 10.1. Cardiology
  • 10.2. Infectious Disease Diagnosis
  • 10.3. Neurology
  • 10.4. Oncology
  • 10.5. Orthopedics

11. Nuclear Imaging Equipment Market, by End-User

  • 11.1. Diagnostic Imaging Centers
  • 11.2. Hospitals & Clinics
  • 11.3. Research Institutes

12. Nuclear Imaging Equipment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nuclear Imaging Equipment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nuclear Imaging Equipment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Nuclear Imaging Equipment Market

16. China Nuclear Imaging Equipment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Absolute Imaging Inc.
  • 17.6. Advanced Accelerator Applications S.A. by Norvatis
  • 17.7. Agfa-Gevaert N.V
  • 17.8. Bayer AG
  • 17.9. Bozlu Holding A. S.
  • 17.10. Bracco Imaging S.p.A.
  • 17.11. Canon Medical Systems Corporation
  • 17.12. CMR Naviscan Corporation
  • 17.13. Cubresa Inc.
  • 17.14. DDD-Diagnostic A/S
  • 17.15. Digirad Corporation
  • 17.16. Edge Medical Solutions Private Limited
  • 17.17. GE HealthCare Technologies Inc.
  • 17.18. Koninklijke Philips N.V.
  • 17.19. Mediso Ltd.
  • 17.20. MR Solutions Ltd.
  • 17.21. Neusoft Medical Systems Co., Ltd.
  • 17.22. PerkinElmer Inc.
  • 17.23. Revvity Inc
  • 17.24. Rigaku Corporation
  • 17.25. Shimadzu Corporation
  • 17.26. Siemens AG
  • 17.27. Surgiceye GmbH
  • 17.28. United Imaging Healthcare Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 117. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 118. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 135. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 136. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 141. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 142. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)